Incremental Reduction in Risk of Death Associated with Use of Guideline-Recommended Therapies in Patients with Heart Failure: A Nested Case-Control Analysis of IMPROVE HF
Fonarow, Gregg C.
Albert, Nancy M.
Curtis, Anne B.
O'Connor, Christopher M.
Walsh, Mary N.
Yancy, Clyde W.
MetadataShow full item record
CitationFonarow, Gregg C., Nancy M. Albert, Anne B. Curtis, Mihai Gheorghiade, Yang Liu, Mandeep R. Mehra, Christopher M. O'Connor, Dwight Reynolds, Mary N. Walsh, and Clyde W. Yancy. 2012. Incremental reduction in risk of death associated with use of guideline-recommended therapies in patients with heart failure: A nested case-control analysis of IMPROVE HF. Journal of the American Heart Association 1(1): 16-26.
AbstractBackground: Several therapies are guideline-recommended to reduce mortality in patients with heart failure (HF) and reduced left ventricular ejection fraction, but the incremental clinical effectiveness of these therapies has not been well studied. We aimed to evaluate the individual and incremental benefits of guideline-recommended HF therapies associated with 24-month survival. Methods and results: We performed a nested case-control study of HF patients enrolled in IMPROVE HF. Cases were patients who died within 24 months and controls were patients who survived to 24 months, propensity-matched 1:2 for multiple prognostic variables. Logistic regression was performed, and the attributable mortality risk from incomplete application of each evidence-based therapy among eligible patients was calculated. A total of 1376 cases and 2752 matched controls were identified. β-Blocker and cardiac resynchronization therapy were associated with the greatest 24-month survival benefit (adjusted odds ratio for death 0.42, 95% confidence interval (CI), 0.34–0.52; and 0.44, 95% CI, 0.29–0.67, respectively). Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, implantable cardioverter-defibrillators, anticoagulation for atrial fibrillation, and HF education were also associated with benefit, whereas aldosterone antagonist use was not. Incremental benefits were observed with each successive therapy, plateauing once any 4 to 5 therapies were provided (adjusted odds ratio 0.31, 95% CI, 0.23–0.42 for 5 or more versus 0/1, P<0.0001). Conclusions: Individual, with a single exception, and incremental use of guideline-recommended therapies was associated with survival benefit, with a potential plateau at 4 to 5 therapies. These data provide further rationale to implement guideline-recommended HF therapies in the absence of contraindications to patients with HF and reduced left ventricular ejection fraction.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:10581158
- HMS Scholarly Articles